Apontis Pharma Forecast, price target & analysts
Apontis Pharma Target price 2025 - Analyst rating & recommendation
Apontis Pharma Classifications & Recommendation:
Apontis Pharma Price Target
| Target Price | €10.20 |
| Price | €10.85 |
| Deviation |
5.99%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Apontis Pharma 2026 .
The average Apontis Pharma target price is €10.20.
This is
5.99%
register free of charge
€10.50
3.23%
register free of charge
€10.10
6.91%
register free of charge
|
|
| A rating was issued by 9 analysts: 0 Analysts recommend Apontis Pharma to buy, 2 to hold and 7 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Apontis Pharma stock has an average upside potential 2026 of
5.99%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million € | 48.47 | 56.00 |
| 31.14% | 15.53% | |
| EBITDA Margin | 7.22% | 12.93% |
| 134.80% | 79.06% | |
| Net Margin | 1.55% | 6.59% |
| 105.06% | 325.89% |
3 Analysts have issued a sales forecast Apontis Pharma 2025 . The average Apontis Pharma sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Apontis Pharma EBITDA forecast 2025. The average Apontis Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 Apontis Pharma Analysts have issued a net profit forecast 2025. The average Apontis Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share € | 0.09 | 0.44 |
| 106.77% | 388.89% | |
| P/E | 24.51 | |
| EV/Sales | 1.37 |
5 Analysts have issued a Apontis Pharma forecast for earnings per share. The average Apontis Pharma EPS is
This results in the following potential growth metrics and future valuations:
Current Apontis Pharma Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Dec 02 2024 |
| WARBURG RESEARCH GMBH |
Locked
➜
Locked
|
Locked | Nov 06 2024 |
| HAUCK AUFHAEUSER INVESTMENT BANKING |
Locked
➜
Locked
|
Locked | Oct 17 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Dec 02 2024 |
|
Locked
WARBURG RESEARCH GMBH:
Locked
➜
Locked
|
Nov 06 2024 |
|
Locked
HAUCK AUFHAEUSER INVESTMENT BANKING:
Locked
➜
Locked
|
Oct 17 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
